Advertisement

90. Kongreß pp 1445-1479 | Cite as

Postersession III

Diabetes
  • W. Waldhäusl
  • K. Czerwenka-Howorka
  • K. Derfler
  • W. Schröcksnadel
  • H. Freyler
  • W. Beischer
  • E. Dittus
  • M. Pfeiffer
  • K. Rett
  • M. Wicklmayr
  • H. Mehnert
  • K. Feilen
  • W. Kerner
  • E. F. Pfeiffer
  • I. Böttger
  • G. Dietze
  • H. G. Velcovsky
  • T. Lietz
  • L. Koch
  • A. Otten
  • J. Neuzner
  • G. Sachse
  • K. Federlin
  • H. Walter
  • E. Biermann
  • W. Bachmann
  • M. Hogan
  • G. Schulz
  • J. Beyer
  • P. Kempf
  • B. Jakober
  • R. M. Schmülling
  • M. Eggstein
  • H. Tillil
  • J. Könneker
  • J. Köbberling
  • R. G. Bretzel
  • M. Richardt
  • A. Menden
  • R. Landgraf
  • M. M. C. Landgraf-Leurs
  • D. Burg
  • A. Kampik
  • W. Land
  • M. Dreyer
  • U. Siemers
  • J. Kühnau
  • H. W. Rüdiger
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 90)

Zusammenfassung

Diabetes mellitus (DM) ist ein klinisches Syndrom, dessen Häufigkeit in den westlichen Industriestaaten auf 1,5–2,5% geschätzt wird [1] und dessen Prävalenz genetisch bedingt in manchen Populationen (Pima-Indianer) allein für den Typ 2 bis zu 35% betragen kann [2]. Im allgemeinen wird jedoch der relative Anteil der nichtinsulinabhängigen (Typ 2) Diabetiker an der Gesamtprävalenz der Zuckerkrankheit mit 80–85% angegeben, so daß nur ein kleiner Anteil dem primär insulinabhängigen Diabetes des Typ 1 zuzuordnen ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Schliack V (1971) Die Verbreitung des Diabetes mellitus: Häufigkeit und Vorkommen in Europa und Amerika. In: Pfeiffer EF (Hrsg) Handbuch des Diabetes mellitus, Bd 2. Lehmanns, München, S 333–364Google Scholar
  2. 2.
    Bennett PH, LeCompte PM, Miller M, Rushforth NB (1976) Epidemiological studies of diabetes in the Pima Indians. Recent Prog Horm Res 32: 333–376PubMedGoogle Scholar
  3. 3.
    Waldhäusl W (1983) Therapeutische Möglichkeiten zur Normalisierung der Glukosehomöostase bei Diabetikern. Hämostaseologie 3: 140–148Google Scholar
  4. 4.
    Miller Leone V, Goldstein J (1972) More efficient care of diabetic patients in a country-hospital setting. N Engl J Med 286: 1388–1391PubMedCrossRefGoogle Scholar
  5. 5.
    Green A, Solander F (1984) Epidemiological studies of diabetes mellitus in Denmark. 6. Use of hospital services by insulin treated patients. Diabetologia 26: 195–198PubMedGoogle Scholar
  6. 6.
    Deckert T, Poulsen JE, Larsen M (1979) The prognosis of insulin dependent diabetes mellitus and the importance of supervision. Acta Med Scand (Suppl) 624: 48–53Google Scholar
  7. 7.
    Panzram G, Zabel-Langhennig R (1981) Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 20: 587–591PubMedCrossRefGoogle Scholar
  8. 1.
    Bagdade JD et al. (1967) The significance of basal insulin levels in evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46: 1549–1557PubMedCrossRefGoogle Scholar
  9. 2.
    Beischer W et al. (1984) The therapeutic and prognostic relevance of the fast beta-cell stimulation capacity. In: Melchionda N, Horwitz DC, Schade DS (eds) Recent advances in obesity and diabetes research. Raven Press, New York, p 1Google Scholar
  10. 3.
    Beischer W et al. (1976) C-Peptid als Parameter für die orale Diabetestherapie. Verh Dtsch Ges Inn Med 82: 791–794PubMedGoogle Scholar
  11. 4.
    Beischer W et al. (1978) Humanes C-Peptid, Teil III: Sekretionsdynamik der Beta-Zellen erwachsener Diabetiker nach Glibenclamid-Glukose i.v. Klin Wochenschr 56: 111–120PubMedCrossRefGoogle Scholar
  12. 5.
    Bodansky HJ et al. (1981) Plasma C-peptide in long-standing type 1 diabetics with and without microvascular disease. Diabete Metab 7: 265–269PubMedGoogle Scholar
  13. 6.
    Fajans SS et al. (1978) Clinical and etiologic heterogeneity of idiopathic diabetes mellitus. Diabetes 27: 1112–1125PubMedCrossRefGoogle Scholar
  14. 7.
    Holman RR, Turner RC (1979) Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes. Diabetes 28: 227–230PubMedCrossRefGoogle Scholar
  15. 8.
    Madsbad S (1983) Prevalence of residual B-cell function and its metabolic consequences in type 1 (insulin-dependent) diabetes. Diabetologia 24: 141–147PubMedGoogle Scholar
  16. 9.
    Madsbad S et al. (1981) Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 210: 153–156PubMedCrossRefGoogle Scholar
  17. 10.
    Pfeifer MA et al. (1981) Insulin secretion in diabetes mellitus. Am J Med 70: 579–588PubMedCrossRefGoogle Scholar
  18. 11.
    Pfeiffer EF et al. (1961) Über die Bestimmung von Insulin im Blute am epididymalen Fettanhang der Ratte mit Hilfe markierter Glukose. IV. Die Dynamik der Insulinsekretion des Stoffwechselgesunden und des Altersdiabetikers nach wiederholter Belastung mit Glukose, Sulfonylharnstoffen und menschlichem Wachstumshormon, ein Beitrag zur Pathogenese des menschlichen Altersdiabetes. Klin Wochenschr 39: 415–426PubMedCrossRefGoogle Scholar
  19. 12.
    Pfeiffer EF, Raptis S (1972) Controlled extension of oral antidiabetic therapy on former insulin-dependent diabetics by means of the combined i.v. glibenclamide-glucose test. Diabetologia 8: 41–47PubMedCrossRefGoogle Scholar
  20. 13.
    Pfeiffer EF et al. (1974) Einmalige intravenöse Glibenclamid-Glukose Belastung als Vorhersagetest. Dtsch Med Wochenschr 99: 1281–1294PubMedCrossRefGoogle Scholar
  21. 14.
    Smith RBW et al. (1979) C-peptide response to glucagon in diabetics with and without complications. NZ Med J 89: 304–306Google Scholar
  22. 15.
    Tchobroutsky G (1978) Relation of diabetic control to development of microvascular complications. Diabetologia 15: 143–152PubMedCrossRefGoogle Scholar
  23. 1.
    Adeniyi RO, Jones RH, Barnes DG, Gerlis LS, Sönksen PH (1983) Porcine and human insulin (Novo): a comparison of their metabolism and hypoglycaemic activity in normal man. Diabetes Care (Suppl 1 ) 6: 9–12Google Scholar
  24. 2.
    Arias P, Navascues I, Schäfauer G, Kerner W, Pfeiffer E (1983) Vergleichende Untersuchungen zur Wirksamkeit von semisynthetischem Humaninsulin und hochgereinigtem Schweineinsulin. Wien Med Wochenschr (Suppl) 76: 3Google Scholar
  25. 3.
    Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A (1981) Pharmacokinetics of biosynthetic human insulin and characteristics of its effect. Diabetes Care 4: 168–169PubMedCrossRefGoogle Scholar
  26. 4.
    Dietze G, Wicklmayr M, Hepp KD, Bogner W, Mehnert H, Czempiel H, Henftling HG (1976) On gluconeogenesis of human liver. Accelerated hepatic glucose formation induced by increased precursor supply. Diabetologia 12: 555–561PubMedCrossRefGoogle Scholar
  27. 5.
    Gutmann J, Rachel V, Brundl G (1969) Vergleichende Untersuchungen mit neuen rheographischen und plethysmographischen Durchblutungsmageräten. Elektromedizin 87: 38Google Scholar
  28. 6.
    Johansen K (1983) Human insulin — Medical progress? Metabolism 32: 528–532PubMedCrossRefGoogle Scholar
  29. 7.
    Owens DR, Jones MK, Hayes TM, Heding LG, Alberti KGMM, Home PD, Burrin JM, Newcombe RG (1981) Human insulin: Study of safety and efficacy in man. Br J Med 282: 1264–1266CrossRefGoogle Scholar
  30. 8.
    Sonnenberg GE, Berger M (1983) Human insulin: Much ado about one amino acid— Diabetologia 25: 457–459Google Scholar
  31. 9.
    Wicklmayr M, Dietze G (1979) Untersuchungen zur Insulinsensitivität von Leber und Muskulatur des Menschen. Verh Dtsch Ges Inn Med 85: 993–997Google Scholar
  32. 1.
    Christiansen AH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies. Horm Metab Res 5: 147–154PubMedCrossRefGoogle Scholar
  33. 2.
    Federlin K, Velcovsky HG (1974) IgE-Antikörper bei Patienten mit Insulinallergie. Verh Dtsch Ges Inn Med 80: 1613–1617PubMedGoogle Scholar
  34. 3.
    Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S (1983) Immunogenicity of recombinant DNA human insulin. Diabetologia 25: 465–469PubMedCrossRefGoogle Scholar
  35. 4.
    Gambhir K, Archer J, Carter L (1977) Insulin radioreceptor assay or human erythrocytes. Clin Chem 23: 1590–1595PubMedGoogle Scholar
  36. 5.
    Laube H, Svedberg J, Velcovsky HG, Federlin K (1981) Biosynthetisches Humaninsulin — seine Wirkung auf Blutzucker, C-Peptid und Plasmacortisol beim Menschen. Verh Dtsch Ges Inn Med 87: 148–150Google Scholar
  37. 6.
    Schluter KJ (1983) Humaninsulin. Diabetes-Praxis 7: 1–7Google Scholar
  38. 7.
    Velcovsky HG, Federlin K (1982) Insulin specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin. Diabetes Care 5: 126–132PubMedCrossRefGoogle Scholar
  39. 1.
    Andersen O (1975) The immunogenic properties of highly purified insulin preparations. The clinical importance of insulin-binding antibodies. Acta Endocrinol (Kbh) 78: 723–735Google Scholar
  40. 2.
    Asplin CM et al. (1978) Change of insulin dosage, circulating free bound insulin and insulin antibodies on transferring diabetics from conventional to highly purified insulin. Diabetologia 14: 99–105PubMedCrossRefGoogle Scholar
  41. 3.
    Christiansen AH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methological studies. Horm Metab Res 5: 147–154PubMedCrossRefGoogle Scholar
  42. 4.
    Deckert T, Lorup B (1976) Regulation of brittle diabetes by a pre-planned insulin infusion programme. Diabetologia 12: 537–579CrossRefGoogle Scholar
  43. 5.
    Deckert T, Lauritzen T (1982) Assessment of one-year insulin pump therapy. Diabetologia 23: 162–163Google Scholar
  44. 6.
    Federlin K et al. (1983) Immunologische Beobachtungen bei Primär-and Sekundärbehandlung von Diabetikern mit Humaninsulin. Miinch Med Wochenschr 125: 101–107Google Scholar
  45. 7.
    Irsigler K, Kritz H (1979) Long-term continous intravenous insulin therapy with a portable insulin dosage regulating apparatus. Diabetes 28: 196–203PubMedCrossRefGoogle Scholar
  46. 8.
    Kurtz AB et al. (1978) Insulin-binding antibody: Reaction differences with bovine and porcine insulins. Diabetologia 15: 19–22PubMedCrossRefGoogle Scholar
  47. 9.
    Koivisto VA et al. (1983) No evidence of amyloidosis in type I diabetics treated with continuous subcutaneous insulin infusion. Diabetes 32: 88–90PubMedCrossRefGoogle Scholar
  48. 10.
    Levandoski LA et al. (1982) Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diab Care 5: 6–10CrossRefGoogle Scholar
  49. 11.
    Lougheed WD et al. (1980) Insulin aggregation in artificial delivery systems. Diabetologia 19: 1–9PubMedCrossRefGoogle Scholar
  50. 12.
    Mauer SM et al. (1983) Failure to finf amyloidosis in dogs treated with long-term intravenous insulin delivered by a totally implantable pump. Diabetologia 25: 448–450PubMedCrossRefGoogle Scholar
  51. 13.
    Neuzner J et al. (1981) Short term treatment with a portable insulin pump influences diabetic autonomic neuropathy. Diabetologia 21: 308Google Scholar
  52. 14.
    Neuzner J et al. (1983) Long-term intravenous insulin infusion therapy in patient with insulin dependent diabetes mellitus and Addison’s disease. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 103–109Google Scholar
  53. 15.
    Pickup JC et al. (1978) Continous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1: 204–207PubMedCrossRefGoogle Scholar
  54. 16.
    Pietri A et al. (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671PubMedCrossRefGoogle Scholar
  55. 17.
    Sachse G et al. (1983) Treatment with a portable insulin infusion system influences autonomic diabetic neuropathy of the cardiovascular system. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 201–203Google Scholar
  56. 18.
    Schiffrin A, Belmonte M (1982) Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. Diabetes 31: 255–264PubMedCrossRefGoogle Scholar
  57. 19.
    Schulz G et al. (1983) Implantable insulin infusion devices in the therapy of type I diabetes. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 110–118Google Scholar
  58. 20.
    Slama G et al. (1974) One to five days of continuous intravenous insulin infusion on seven diabetic patients. Diabetes 23: 732–739PubMedGoogle Scholar
  59. 21.
    Teutsch SM et al. (1984) Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med 310: 361–368PubMedCrossRefGoogle Scholar
  60. 22.
    Velcovsky HG, Federlin K (1982) Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin. Diab Care 5: 126–128CrossRefGoogle Scholar
  61. 23.
    Viberti G et al. (1981) Correction of exercise induced microalbuminuria in insulin dependent diabetics after 3 weeks of subcutaneous insulin infusion. Diabetes 30: 818–823PubMedCrossRefGoogle Scholar
  62. 24.
    Williamson JR et al. (1982) Secondary amyloidosis in (beagle) dogs receiving intravenous insulin via mechanical pumps. Diabetes 31: 50AGoogle Scholar
  63. 25.
    Yue DK et al. (1975) Antigenicity of “Monocomponent” pork insulin in diabetic subjects. Diabetes 24: 625–632PubMedCrossRefGoogle Scholar
  64. 1.
    Boulton AJM, Drury J, Clarke B, Ward JD (1982) Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diab Care 5: 386–390CrossRefGoogle Scholar
  65. 2.
    Irsigler K, Kunz KM, Owens DR, Regal H (eds) New approaches to insulin therapy. Lancaster, MTP Press Ltd., pp 437–441Google Scholar
  66. 3.
    Pietri A, Ehle AL, Raskin P (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671PubMedCrossRefGoogle Scholar
  67. 4.
    Tolaymat A, Roque JL, Rosso LS Jr (1982) Improvement of diabetic peripheral neuropathy with the portable insulin infusion pump. South Med J 75: 185–189PubMedCrossRefGoogle Scholar
  68. 5.
    White NH, Skor D, Santiago JV (1982) Long-term effect of intensive insulin therapy (ITT) on peripheral (PN) and autonomic (AN) neuropathy in insulindependent diabetics (IDDs) (Abstract). Diabetes (Suppl) 31: 66ACrossRefGoogle Scholar
  69. 1.
    Kästner E, Beyer J, Hassinger W, Schulz G, Cordes U (1980) Untersuchungen zum basalen und nahrungsabhängigen Insulinbedarf bei Diabetikern während kontinuierlicher intravenöser Insulininfusion mit tragbaren Minipumpen im Kurz-und Langzeitversuch. Aktuel Endokrinol Stoffwechselkr 1: 185Google Scholar
  70. 2.
    Blackshear PJ, Rohde TD, Prosl F, Buchwald H (1979) The implantable pump: a new concept of drug delivery. Med Prog Technol 6: 149PubMedGoogle Scholar
  71. 3.
    Buchwald H, Rohde TD, Dorman FD, Skagoon JG, Wigness BD, Blackshear PJ, Varco RL (1980) A totally implantable drug infusion device: Laboratory and clinical experience using a model with single flow rate and new design for modulation insulin infusion. Diab Care 3: 351–358CrossRefGoogle Scholar
  72. 4.
    Schulz G, Beyer J, Hogan M, Cordes U, Kempf P (1983) Implantable insulin infusion devices in the therapy of type I diabetics. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion system. Urban und Schwarzenberg, München Wien Baltimore, p 110Google Scholar
  73. 5.
    Service FJ, Molnar GD, Rosewear JW, Ackermann E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 19: 644–655PubMedGoogle Scholar
  74. 6.
    Schlichtkrull JO, Munk O, Jersild M (1965) The M-value an index of blood-sugar control in diabetics. Acta Med Scand 177: 95–102PubMedCrossRefGoogle Scholar
  75. 7.
    Geisen K, Gerlach MH, Keil M (1981) Morphological in pancreatectomized dogs within an implanted insulin dosing device: Tissue reactions to the pump housing and to the vascular catheter. Horm Metab Res 15: 4–10CrossRefGoogle Scholar
  76. 8.
    Kashiwagi S, Morguet A, Schmitt V, Schonwald F, Kiesel U, Herberg L, Müntefering H (1981) Komplikationen der kontinuierlichen Insulininfusion bei Ratten. Acta Endokrinol (Kbh) 2: 95Google Scholar
  77. 9.
    Irsigler K, Kritz H (1982) Improvement of metabolic control with implanted insulin delivery devices in five diabetic patients-Long term feasibility. Diabetes 31: 654Google Scholar
  78. 10.
    Kritz H, Hagemüller G, Lovett R, Irsigler K (1983) Implanted constant basal rate insulin infusion devices for type 1 (insulin-dependent) diabetic patients. Diabetologia 25: 78–81PubMedCrossRefGoogle Scholar
  79. 11.
    Pozza G, Spotti D, Micossi P, Christallo M, Melandri M, Piatri PM, Monti LD, Pontiroli AE (1983) Long-term continuous intraperitoneal insulin treatment in brittle diabetes. Br Med J 286: 255–256CrossRefGoogle Scholar
  80. 1.
    Krzentowski G, Pirnay F, Pallikarakis N, Luyckx AS, Lacroix M, Mosora F, Lefebvre PJ (1981) Glucose utilization during exercise in normal and diabetic subjects. Diabetes 30: 983–989PubMedCrossRefGoogle Scholar
  81. 2.
    Berger M, Berclefeld P, Clippers HJ, Drost H, Kley HK, Muller WA, Wiegelmann W, Zimmermann-Teltschow, Gries A, Krüskemper HL, Zimmermann H (1977) Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 13: 355–365PubMedCrossRefGoogle Scholar
  82. 3.
    Koivisto VA, Felig P (1977) Effects of exercise on insulin release from injection sites in diabetic man. Diabetes 26: 357–361Google Scholar
  83. 4.
    Martin MJ, Robbins DC, Bergenstal R, La Grange B, Rubenstein AH (1982) Absence of exercise induced hypoglycemia in type I diabetic patients during maintenance of normoglycemia by short term open loop insulin infusion. Diabetologia 23: 337–342CrossRefGoogle Scholar
  84. 5.
    Costill DL, Benett A, Branam G, Eddy D (1973) Glucose ingestion at rest and during prolonged exercise. J Appl Physiol 34: 764–769PubMedGoogle Scholar
  85. 6.
    Caron D, Poussier P, Marliss EB, Zinman B (1982) The effect of postprandial exercise on meal related glucose intolerance in insulin dependent diabetic individuals. Diab Care 5: 364–369Google Scholar
  86. 1.
    WHO Expert Committee on Diabetes Mellitus (1980) Second report. WHO Technical Report Series 646, GenevaGoogle Scholar
  87. 2.
    Fajans SS, Conn JW (1959) The early recognition of diabetes mellitus. Ann NY Acad Sci 82: 208–218PubMedCrossRefGoogle Scholar
  88. 3.
    WHO Expert Committee on Diabetes Mellitus (1956) First report. WHO Technical Report Series 310, GenevaGoogle Scholar
  89. 4.
    Jarrett RJ, Keen H, Fuller JH, McCartney M (1979) Worsening to diabetes in men with impaired glucose tolerance („borderline diabetes“). Diabetologia 16: 25–30PubMedCrossRefGoogle Scholar
  90. 5.
    Keen H, Jarrett RJ, McCartney P (1982) The ten-year follow-up of the Bedford survey (1962–1972): Glucose tolerance and diabetes. Diabetologia 22: 73–78PubMedCrossRefGoogle Scholar
  91. 6.
    Köbberling J, Appels A, Köbberling G, Creutzfeldt W (1969) Glucosebelastungstests bei 727 Verwandten 1. Grades von Altersdiabetikern. Dtsch Med Wochenschr 94: 416–421PubMedCrossRefGoogle Scholar
  92. 7.
    Köbberling J, Kattermann R, Arhold A (1975) Follow up of „non diabetic“ relatives of diabetics by retesting oral glucose tolerance after 5 years. Diabetologia 11: 451–456PubMedCrossRefGoogle Scholar
  93. 8.
    Köbberling J (1980) Zur Wertigkeit des oralen Glucosetoleranztests. Internist 21: 213–219PubMedGoogle Scholar
  94. 9.
    Köbberling J (1982) Der prädiktive Wert diagnostischer Maßnahmen. Dtsch Med Wochenschr 107: 591–595PubMedCrossRefGoogle Scholar
  95. 10.
    Haslbeck M (1981) Diagnostische Probleme bei Diabetes mellitus. Internist 22: 187–196PubMedGoogle Scholar
  96. 1.
    Brekke IB, Aluments J, Sundler F (1983) The duct-ligated pancreas transplant and its effect on the islet cellular composition of the host pancreas. Cell Tissue Res 231: 205–213PubMedCrossRefGoogle Scholar
  97. 2.
    Bretzel RG, Federlin K (1980) Islet transplantation in experimental diabetes mellitus of the rat. Biochemical and morphological findings. In: Bibergeil H, Zühlke H, Poser U (eds) Early diabetes. Pathogenesis, diagnosis, prevention. Central Institute for Diabetes „Gerhardt Katsch`, Karlsburg, p 290Google Scholar
  98. 3.
    Bretzel RG, Manns E, Schomber C, Federlin K (1978) Die Leber als Implantationsort far Langerhanssche Inseln beim experimentellen Diabetes mellitus. Verh Dtsch Ges Inn Med 84: 1213–1217PubMedGoogle Scholar
  99. 4.
    Kramp RC, Burr IM (1981) Subcutaneous, isogeneic transplantation of duct-ligated pancreas in streptozotocin-diabetic mice. Relationships between carbohydrate tolerance and hormone content in transplant or host pancreas. Diabetes 30: 857–864PubMedCrossRefGoogle Scholar
  100. 5.
    Trimble ER, Karakash C, Malaisse-Lagae F, Vassutine I, Orci L, Renold AE (1980) Effects of intraportale islet transplantation on the transplanted tissue and the recipient pancreas. I. Functional studies. Diabetes 26: 341–347CrossRefGoogle Scholar
  101. 1.
    Rüdiger, HW, Dreyer M, Kühnau J, Bartelheimer H (1983) Familial insulin-resistant diabetes secondary to an affinity defect of the insulin receptor. Hum Genet 64: 407–411PubMedCrossRefGoogle Scholar
  102. 2.
    Pilch PF, Czech MP (1979) Interaction of cross-linking agents with the insulin effector system of isolated fat cells. J Biol Chem 254: 3375–3381PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • W. Waldhäusl
    • 1
  • K. Czerwenka-Howorka
    • 1
  • K. Derfler
    • 1
  • W. Schröcksnadel
    • 1
  • H. Freyler
    • 1
  • W. Beischer
    • 2
  • E. Dittus
    • 2
  • M. Pfeiffer
    • 2
  • K. Rett
    • 2
  • M. Wicklmayr
    • 2
  • H. Mehnert
    • 2
    • 8
  • K. Feilen
    • 3
  • W. Kerner
    • 4
  • E. F. Pfeiffer
    • 4
  • I. Böttger
    • 5
  • G. Dietze
    • 6
  • H. G. Velcovsky
    • 7
  • T. Lietz
    • 7
  • L. Koch
    • 7
  • A. Otten
    • 7
  • J. Neuzner
    • 7
  • G. Sachse
    • 7
  • K. Federlin
    • 6
    • 13
  • H. Walter
    • 8
  • E. Biermann
    • 8
  • W. Bachmann
    • 8
  • M. Hogan
    • 9
  • G. Schulz
    • 10
  • J. Beyer
    • 10
  • P. Kempf
    • 10
  • B. Jakober
    • 11
  • R. M. Schmülling
    • 11
  • M. Eggstein
    • 11
  • H. Tillil
    • 12
  • J. Könneker
    • 12
  • J. Köbberling
    • 12
  • R. G. Bretzel
    • 13
  • M. Richardt
    • 13
  • A. Menden
    • 13
  • R. Landgraf
    • 14
  • M. M. C. Landgraf-Leurs
    • 14
  • D. Burg
    • 14
  • A. Kampik
    • 14
  • W. Land
    • 14
  • M. Dreyer
    • 15
  • U. Siemers
    • 15
  • J. Kühnau
    • 15
  • H. W. Rüdiger
    • 15
  1. 1.1. Med. Univ.-Klinik, Abt. für Klin.Endokrinologie und Diabetes mellitus, Institut für Klin. Chemie und der 1. Univ.-AugenklinikWienDeutschland
  2. 2.Abt. Innere Medizin I, KlinikumUniversität UlmDeutschland
  3. 3.RechenzentrumUniversität UlmDeutschland
  4. 4.Forschergruppe DiabetesIII. Med. Abt. Krankenhaus München-SchwabingDeutschland
  5. 5.Klinikum rechts der IsarTU MünchenDeutschland
  6. 6.Forschergruppe DiabetesRot-Kreuz-KrankenhausMünchenDeutschland
  7. 7.III. Med. Klinik und Poliklinik, Zentrum für Innere MedizinJustus-Liebig-UniversitätGießenDeutschland
  8. 8.Forschergruppe DiabetesIII. Med. Abt. des Städt. Krankenhauses München-SchwabingMünchenDeutschland
  9. 9.Abt. für Innere Medizin, Endokrinologie und Stoffwechsel, KlinikumJohannes-Gutenberg-UniversitätMainzDeutschland
  10. 10.Stadtkrankenhaus RüsselsheimDeutschland
  11. 11.Med. Univ.-Klinik TübingenDeutschland
  12. 12.Abt. für Gastroenterologie und Stoffwechsel, Med. Klinik und PoliklinikUniversität GöttingenDeutschland
  13. 13.III. Med. Klinik und PoliklinikJustus-Liebig-UniversitätGießenDeutschland
  14. 14.MünchenDeutschland
  15. 15.Med. Kern- und PoliklinikUniversität HamburgDeutschland

Personalised recommendations